Vijay Mohan | Cancer Drug Discovery | Innovative Research Award

Published-on by Indian Scientist

Innovative Research Award

Vijay Mohan
Galgotias University

Vijay Mohan
Affiliation Galgotias University
Country India
Scopus ID 57472028500
Documents 2
Citations 23
h-index 2
Subject Area Cancer Drug Discovery
Event Indian Scientist Awards

Vijay Mohan is associated with Galgotias University, India, and is engaged in research related to Cancer Drug Discovery. His academic work focuses on scientific approaches that contribute to understanding therapeutic targets, drug development strategies, and translational biomedical research. Through scholarly publications and research dissemination, he has contributed to the growing body of knowledge supporting advancements in oncology and pharmaceutical sciences.[1]

Abstract

The Innovative Research Award recognizes researchers who demonstrate originality, scientific rigor, and meaningful scholarly contributions. Vijay Mohan’s research profile reflects engagement in Cancer Drug Discovery, a field that integrates biomedical science, medicinal chemistry, pharmacology, and computational approaches to identify and develop effective therapeutic interventions. His publication and citation record illustrates active participation in scientific inquiry and knowledge dissemination within the biomedical research community.[1][2]

Keywords

Cancer Drug Discovery; Oncology Research; Therapeutic Development; Pharmaceutical Sciences; Biomedical Innovation; Precision Medicine; Drug Design; Translational Research; Cancer Therapeutics; Innovative Research.

Introduction

Cancer remains one of the most significant global health challenges, creating an ongoing need for innovative therapeutic strategies and improved treatment approaches. Cancer Drug Discovery encompasses multidisciplinary efforts directed toward identifying novel compounds, therapeutic targets, and personalized treatment methodologies. Researchers working in this field contribute to advancements that support both fundamental scientific understanding and practical clinical applications.[2]

Research Profile

Vijay Mohan is affiliated with Galgotias University and has established a documented research presence within Cancer Drug Discovery. According to available scholarly indicators, his profile includes two indexed publications, twenty-three citations, and an h-index of two. These metrics reflect research visibility and participation in academic discourse within biomedical and pharmaceutical research domains.[1]

  • Research focus on cancer therapeutics and drug discovery.
  • Interest in translational and biomedical research methodologies.
  • Contribution to scientific publication and scholarly communication.
  • Participation in interdisciplinary healthcare research initiatives.

Research Contributions

Research contributions within Cancer Drug Discovery support the identification of novel therapeutic compounds and improve understanding of disease mechanisms. Scientific efforts in this area often involve target validation, medicinal chemistry, molecular biology, and pharmacological evaluation. Such contributions assist in the development of more effective and personalized treatment strategies for cancer patients.[2]

  • Investigation of therapeutic targets relevant to oncology.
  • Support for innovative approaches to drug development.
  • Contribution to evidence-based biomedical research.
  • Participation in scientific initiatives focused on healthcare advancement.

Publications

The publication record associated with Vijay Mohan reflects scholarly engagement within biomedical and pharmaceutical research. Publications serve as an important mechanism for communicating scientific findings, facilitating peer review, and supporting future investigations in cancer-related research fields.[1]

  1. Research publications related to cancer therapeutics.
  2. Scientific articles supporting drug discovery initiatives.
  3. Peer-reviewed contributions to biomedical literature.
  4. Collaborative research outputs within healthcare sciences.

Research Impact

Research impact may be evaluated through scholarly publications, citations, academic visibility, and contribution to scientific advancement. The citation record associated with Vijay Mohan indicates engagement with the research community and demonstrates that his work has contributed to ongoing scientific discussions within cancer-related biomedical research.[1]

Award Suitability

The Innovative Research Award recognizes researchers whose scholarly activities demonstrate originality, scientific relevance, and meaningful academic contribution. Based on available research indicators and documented scientific engagement, Vijay Mohan exhibits characteristics aligned with innovative research practice through his involvement in Cancer Drug Discovery and biomedical research initiatives. These attributes support consideration within research recognition and excellence programs.[1]

Conclusion

Vijay Mohan’s research profile reflects continued engagement in Cancer Drug Discovery and biomedical research. Through scholarly publication, scientific communication, and contributions to oncology-related investigations, he participates in efforts aimed at advancing therapeutic innovation and healthcare outcomes. The Innovative Research Award provides an appropriate framework for recognizing such scholarly contributions and encouraging continued research excellence.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Vijay Mohan, Author ID 57472028500. Scopus. https://www.scopus.com/authid/detail.uri?authorId=57472028500
  2. Role of Transcription Factor BEND3 and Its Potential Effect on Cancer Progression
    https://www.mdpi.com/2072-6694/15/14/3685

Guruvayoorappan C | Cancer | Outstanding Scientist Award

Published-on by Indian Scientist

Dr. Guruvayoorappan C | Cancer | Outstanding Scientist Award

Regional Cancer Centre, Thiruvananthapuram | India

Dr. Guruvayoorappan C is an accomplished Associate Professor at the Division of Cancer Research, Regional Cancer Centre, Thiruvananthapuram, specializing in cancer biology, immunology, and biotechnology. He holds advanced degrees in Biotechnology, Biochemistry, Botany, and Immunology, with a Ph.D. from Mahatma Gandhi University and postdoctoral research under the UGC Research Award Scheme. With over 20 years of research and 17 years of teaching experience, he has guided several Ph.D. scholars across reputed universities. His extensive contributions include 110 peer-reviewed publications, with 4096 citations, an h-index of 34, and an i10-index of 73, reflecting his impact in oncology and life sciences. His innovative research focuses on cancer immunomodulation, nanomedicine, tumor angiogenesis, and molecular mechanisms of metastasis. He has successfully led multiple government-funded research projects from DBT, ICMR, DST-SERB, and UGC, alongside patents in wound-healing nano scaffolds. Dr. Guruvayoorappan’s work has earned him prestigious honors including the UGC Research Award, DST-Early Career Research Award, ISTE-Periyar Best Teacher Award, and several fellowships from leading scientific academies. His research continues to advance understanding of tumor biology and therapeutic strategies, establishing him as a leading figure in cancer and immunological research.

Profile: Google Scholar

Featured Publications

Aggarwal, B. B., Surh, Y. J., & Shishodia, S. (Eds.). (2007). The molecular targets and therapeutic uses of curcumin in health and disease. Springer Science & Business Media.

Menon, S. S., Guruvayoorappan, C., Sakthivel, K. M., & Rasmi, R. R. (2019). Ki-67 protein as a tumour proliferation marker. Clinica Chimica Acta, 491, 39–45.

Dhanisha, S. S., Guruvayoorappan, C., Drishya, S., & Abeesh, P. (2018). Mucins: Structural diversity, biosynthesis, its role in pathogenesis and as possible therapeutic targets. Critical Reviews in Oncology/Hematology, 122, 98–122.

Rasmi, R. R., Sakthivel, K. M., & Guruvayoorappan, C. (2020). NF-κB inhibitors in treatment and prevention of lung cancer. Biomedicine & Pharmacotherapy, 130, 110569.

Kuttan, G., Hari Kumar, K. B., Guruvayoorappan, C., & Kuttan, R. (2007). Antitumor, anti-invasion, and antimetastatic effects of curcumin. In B. B. Aggarwal, Y. J. Surh, & S. Shishodia (Eds.), The molecular targets and therapeutic uses of curcumin in health and disease (pp. xx–xx). Springer Science & Business Media.

Ruby Anto | Cancer | Best Researcher Award

Published-on by Indian Scientist

Dr. Ruby Anto | Cancer | Best Researcher Award

Centre of Excellence in Nutraceuticals, Government of Kerala | India

Dr. Ruby John Anto is a distinguished biomedical scientist whose pioneering research has significantly advanced the field of cancer biology and nutraceutical sciences. She holds a Ph.D. in Biochemistry from Amala Cancer Research Centre, Thrissur, and has served in various scientific capacities at the Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, including Scientist G, before taking up her current role as Chief Scientist at the Centre of Excellence in Nutraceuticals under KSCSTE, Government of Kerala, and Honorary Scientist at the Institute of Advanced Virology. Her research focuses on the bioprospecting of natural compounds with therapeutic potential against cancer, inflammation, and lifestyle diseases. A highlight of her work is the discovery of Uttroside B, a potent anticancer compound that earned “Orphan Drug” designation from the US FDA for liver cancer treatment and is patented internationally. With an h-index of 42, i10-index of 63, and over 7,600 citations from 80+ international publications, Dr. Anto’s work has received widespread recognition. She has been honored with national and international awards, including the National Woman Bio-Scientist Award and the Keystone Symposia Global Health Award. Her scientific leadership continues to inspire innovation in cancer research, nutraceuticals, and translational medicine.

Profiles: Google Scholar | Scopus

Featured Publications

Ruby, A. J., Kuttan, G., Babu, K. D., Rajasekharan, K. N., & Kuttan, R. (1995). Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Letters, 94(1), 79–83. https://doi.org/ (Cited by: 1571)

Anto, R. J., Mukhopadhyay, A., Denning, K., & Aggarwal, B. B. (2002). Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: Its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis, 23(1), 143–150. https://doi.org/ (Cited by: 593)

Anto, R. J., Sukumaran, K., Kuttan, G., Rao, M. N. A., Subbaraju, V., & Kuttan, R. (1995). Anticancer and antioxidant activity of synthetic chalcones and related compounds. Cancer Letters, 97(1), 33–37. https://doi.org/ (Cited by: 456)

Oommen, S., Anto, R. J., Srinivas, G., & Karunagaran, D. (2004). Allicin (from garlic) induces caspase-mediated apoptosis in cancer cells. European Journal of Pharmacology, 485(1–3), 97–103. https://doi.org/ (Cited by: 393)

Anto, R. J., Mukhopadhyay, A., Shishodia, S., Gairola, C. G., & Aggarwal, B. B. (2002). Cigarette smoke condensate activates nuclear transcription factor-κB through phosphorylation and degradation of IκBα: Correlation with induction of cyclooxygenase-2. Carcinogenesis, 23(9), 1511–1518. https://doi.org/ (Cited by: 335)